Prospects for the Medical Use of Interferon in 1984 by Postic, Bosko & Arroyo, Julio C.
Henry Ford Hospital Medical Journal 
Volume 32 Number 2 Article 7 
6-1984 
Prospects for the Medical Use of Interferon in 1984 
Bosko Postic 
Julio C. Arroyo 
Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal 
 Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons 
Recommended Citation 
Postic, Bosko and Arroyo, Julio C. (1984) "Prospects for the Medical Use of Interferon in 1984," Henry 
Ford Hospital Medical Journal : Vol. 32 : No. 2 , 116-122. 
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol32/iss2/7 
This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has 
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health 
System Scholarly Commons. 
Henry Ford Hospital Med J 
Vol. 32, No. 2, 1984 
Prospects for the Medical Use of Interferon in 1984 
Bosko Postic, MD* and Julio C. Arroyo, MD" 
Interferon, a natural and wide spectrum antiviral poly-
peptide that was discovered in 1957, has been ex-
tensively described. In addition to its antiviral effect, 
interferon has been found to suppress tumor growth 
and modulate the immune response. Until 1980, inter-
feron was primarily prepared for clinical trials in human 
leukocytes derived from the buffy coat of whole blood. 
A major breakthrough occurred in the late 1970s when 
human interferon was produced by DNA recombinant 
methods in such heterologous cells as bacteria (genetic 
engineering). Interferon is not commercially available 
in 1984, but it may, based on clinical trials in humans, 
become part of combination therapy for certain can-
cers. It also holds promise for the treatment of chronic 
active hepatitis due to hepatitis B virus. Interferon has 
The Interferon System 
Interferon was discovered as an antiviral protein by 
Isaacs and Lindenmann in 1957 (1). They tried to explain 
the phenomenon of viral interference and found that an 
explanted chorioallantoic membrane of the chick em-
bryo could be induced wi th a heat-activated influenza 
virus to elaborate a substance capable of protecting a 
fresh membrane against challenge wi th live homo-
logous virus. In this experiment, the antiviral substance, 
interferon, acted prophylactically, and this t iming of 
application is most effective. 
The importance of interferon in antiviral host defenses 
was hard to def ine, because the inability to generate 
interferon could not be identif ied in various disease 
states. Recently, T-lymphocytes f rom patients wi th ac-
quired immunodeficiency syndrome (AIDS) were also 
found to be deficient in interferon product ion (2). 
Excellent and readable reviews on the biologic and 
virologic aspects of interferon are available and recom-
mended (3-6). The interferon field is central to basic 
virology and b io logy, attract ing a mult id iscipl inary 
group of scientists. In this country, the medical use of 
interferon is l imited to clinical trials. Therefore, the 
American physician may not be familiar wi th the terms 
used by researchers. Some of these wil l be defined 
below in an attempt to outl ine the interferon system. 
Only selected, medically applicable references are cited 
for the interested reader. 
been effective in herpes virus-induced infections, sup-
pressing reactivation episodes as well as the signs and 
symptoms of varicella-zoster virus infections. Prophy-
lactically, but not therapeutically, interferon exerts a 
favorable effect on cytomegalovirus (CMV) infection; 
however, interferon trials are needed in catastrophic 
virus infections where no established (or effective) 
therapy exists. Prophylactic intranasal application of 
interferon was shown to suppress the symptoms of the 
common cold. The role of interferon treatment in the 
acquired immunodeficiency syndrome (AIDS) and its 
associated opportunistic infections and/or Kaposi's 
sarcoma requires further study but shows promise, 
particularly ifor the latter. 
As noted, live or inactivated viruses may serve as in-
ducers of interferon product ion in cultured cells and 
intact animals. Wi th in a few hours after a suspension 
of v i rus is in t ravenously in jected in to an an imal , 
high-titered interferon appears in the plasma (7,8). The 
production of interferon may also be stimulated by syn-
thetic polynucleotides such as the polyinosinic-poly-
cytidylic acid (9), by antigens (10), and by endotoxin (11). 
Interferons are now classified into three types (Table l ) . 
Alpha interferon is produced by human leukocytes 
TABLE 1 
Classifications of Human Interferons 
Type Common Inducer Produced By 
Alpha Virus, live or 
inactivated 
Leukocytes 
(Mononuclear mostly) 
Beta Synthetic, double 
stranded poly-
ribonucleotide 
Fibroblasts in 
culture 
Gamma Antigen T (Helper) Lymphocytes 
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which usually have been stimulated with a myxovirus. 
Until recently it has served as a material for clinical trials 
(4,12). Beta interferon can be stimulated in tissue culture 
with viruses or synthetic polyribonucleotides. Inter-
feron can also be liberated by T-cells upon contact wi th 
ant igen. This l ymphok ine , previously termed " i m -
mune" interferon (5,10), is now called gamma. All three 
interferons are antiviral in their effect, though they 
differ as to their cell source and the method of induc-
t ion. Antigenic determinants are specific to the type and 
identifiable by monoclonal antibody. 
The biologic effects of interferon also constitute a tr iad. 
There is (a) an antiviral effect, (b) an inhibitory effect on 
cellular prol i ferat ion, and (c) an immuno-modulator. 
These effects characterize interferon as a cellular pro-
tein product wi th a high specific activity, about 4 x 10 ' 
mg protein per unit , which is comparable to a hormone 
(5). The specific activity relates to the antiviral effect, 
and this potency could be quantitated and standardized 
as international units through a human interferon stan-
dard preparation f rom the National Institutes of Health. 
The antiviral effect of interferon is not direct. Interferon 
is absorbed on cells and produces an antiviral state in 
them by inducing the synthesis of new proteins. Such a 
protein is the enzyme responsible for the synthesis of a 
new2' ,5 ' isoadenylate, which activates an intracellular 
ribonuclease that is capable of degrading the mes-
senger RNA involved in the biosynthesis o f t he infecting 
virus (13). A protein kinase is also induced which leads 
to phosphorylation and, thereby, depression of an in-
itiation factor needed for viral protein synthesis (14). 
Unlike antibiotics that directly attack bacteria, inter-
feron requires the host cell's participation for its anti-
viral eff ect. 11 fo 11 ows tha t th ise f fec t i s inh ib i to ryandnot 
virucidal. Therefore, the antiviral effect of interferon in 
animal and human cell culture is suppressive and not 
erad icat ive . The pat ient 's preserved i m m u n i t y is 
needed to complete the antiviral effect, that is, lead to 
cure from infection. 
The mechanism o f the cell inhibi tory effect of interferon 
remains unknown. In certain virus-induced tumors, the 
antiviral effect of interferon may also have an indirect 
anti tumor effect. However, interferon is also effective 
in tumors that are not viral in origin (15). The cell in-
hibitory effect of interferon has also expressed itself as a 
side effect in patients treated for leukopenia. For-
tunately, the effects were reversible when interferon 
therapy was discontinued. 
Interferon may be both stimulatory and inhibi tory to 
immune funct ion, depending on antigen stimulation 
t iming (16) and interferon dosage. Interferon may sup-
press antibody formation (17), but it enhances the natu-
ral killer lymphocyte funct ion (5). 
Interferon is also a weak antigen. Antibodies to inter-
feron may sometimes be neutralizing (18), suppressing 
the antiviral and other biologic effects of interferon. 
In most instances, interferon displays an interesting 
characteristic of species specificity by being active (anti-
viral) only in cells of the homologous species. However, 
many interspecies "crosses" have been ident i f ied. 
Cloned Interferon 
As ment ioned, most interferon for clinical trials has 
been produced in human leukocytes by the "Cantell 
me thod" (4,12), as an intentional and ingenuous by-
product of blood banking. Leukocytes are separated 
f rom whole blood and used for the product ion of inter-
feron after interaction wi th the inducer (an inactivated 
myxovirus). The method, however, is quite complex 
and produces a relatively low yield because of the ex-
tensive purif ication required [one unit of b lood (500 ml) 
can produce one mil l ion units of inter feron, or the 
equivalent of 4 micrograms (5)]. Even after this puri-
f ication, the product is semipure. 
Goeddel and co-workers produced human leukocytic 
interferon in bacteria using DNA recombinant tech-
niques (19). They recovered the gene responsible for 
the product ion of interferon in the human leukocyte 
and then cloned it in Escherichia coli after introduction 
by a plasmid. This method allowed major production of 
interferon and the initiation of more extensive clinical 
trials. In addi t ion, interferon could be purif ied from 
other bacterial constituents by the use of monoclonal 
antibody (6). Several groups of molecular geneticists 
achieved similar results concurrently (5). 
Interferon Therapy in Catastrophic Viral Disease 
There is little information regarding the possibility of 
interferon intervention to combat human viral diseases. 
Hence, projections for the therapeutic role of inter-
feron are derived mostly f rom animal studies. 
Experiments with rabbits demonstrated their resistance 
to challenge with street rabies virus when they were 
s t imu la ted to p roduce i n t e r f e r o n by a syn the t ic 
polyr ibonucleot ide. Better effects were seen when the 
injection of the interferon inducer preceded the inocu-
lation of virus than when the treatment was started after 
exposure (20,21). Administrat ion (intravenous or intra-
muscular) of rabbit interferon was also prophylactically 
protective (22). In the same experimental model , ther-
apy with interferon, via intracranial installation by an 
intraventricular cannula, resulted only in prolonging 
the incubation period (23). As to the use of interferon in 
the prophylaxis of rabies in humans, there is already an 
effective immunologic postexposure treatment (24). 
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The prospects for using interferon to treat rabies victims 
seem slim, since victims are recognized late in their 
course when most of the viral-infl icted damage be-
comes irreversible. 
It is conceivable that interferon may be a therapeutic 
option in other catastrophic viral diseases such as those 
produced by Ebola and Lassa fever viruses. Due to the 
location of these cases, atrial of interferon wil l probably 
be limited to individual patients. A laboratory worker, 
treated with antiserum to the virus and large doses of 
interferon, survived the illness produced by the acci-
dental inoculation of Ebola virus (25). However, inter-
feron given experimentally to monkeys who had been 
inoculated with Ebola virus failed to protect them from 
death (26). 
Systemic and intrathecal interferon therapy may be 
wor thwh i le in cases of putat ive viral encephal i t is. 
Prophylaxis wi th interferon may be the only antiviral 
measure feasible after an un immunized person has 
been exposed to an encephalitogenic virus. Mice could 
be protected f rom Japanese B viral encephalitis by 
prophylaxis with an interferon inducer (27). Moreover, 
comb ined immun iza t ion and in ter feron induct ion 
caused enhanced protection in mice challenged with 
that virus (28). 
Interferon in Chronic Hepatitis B Infection 
Merigan and his group at Stanford University have ex-
tensive experience wi th human leukocytic interferon 
and recombinant alpha interferon in chronic hepatitis B 
infection (29-31). Their patients were chronically anti-
genemic with HbsAg and HBeAg, which indicates per-
sistent viremia. Interferon and adenine arabinoside, 
separately and in comb ina t ion , produced antiviral 
effects, the most consistent of which was the sup-
pression of Dane particles in plasma, ie, reduction of 
viremia. Leukocyte interferon and adenine arabinoside 
in combination produced a virologic and a clinical cure 
in three out of 32 patients. Approximately half of the 
patients experienced only transient improvements (30). 
The use of recombinant interferon alpha also allowed 
the titration of the daily intramuscular dose; there was a 
greater suppression of the hepatitis B virus DNA polymer-
ase, ie, a reduction in the magnitude of viremia, with 
higher doses (50 and 68 million units) than with lower 
ones (3 and 9 million units a day, intramuscularly) (31). 
Interferon Treatment with Herpes Infection 
This topic was extensively reviewed by Hirsch and 
Schooley (32). Human leukocyte interferon was effec-
tive in the treatment of herpes zoster in patients with 
cancer (33). A control led trial of prophylactic human 
leukocyte interferon resulted in delayed shedding of 
the cytomegalovirus (CMV) and a lower incidence of 
v i remia after renal t ransplantat ion (34). Inter feron 
reduced the signs of CMV infection in renal transplant 
recipients. Interestingly, opportunist ic superinfections 
by Aspergillus fumigatus and Pneumocystis carinii oc-
curred in patients who were given placebos but not in 
those treated wi th interferon (35). Susceptibility testing 
of six CMV isolates wi th beta interferon revealed that 
this virus was inhibited by interferon in cell culture, but 
to a lesser degree than the very sensitive vesicular 
stomatitis virus (36). Antiviral treatment of disseminated 
CMV illness in renal transplant recipients has not been 
successful thus far (37), and currently there is no rec-
ommended treatment for established CMV infection in 
humans. Investigational purine and pyrimidine analogues 
hold some promise, based on in vitro testing (32). 
Short-course human leukocyte interferon was effective 
in the treatment of herpes zoster in patients with can-
cer. Antiviral effects could be observed in a placebo-
contro l led, randomized, double-bl ind trial involving 
only 48 hours of therapy (38). 
A reactive herpes simplex infection could be prevented 
by human leukocyte interferon administered before an 
operation was performed on the trigeminal root (39,40). 
In this well-conducted trial by the investigators f rom 
Pittsburgh, an intramuscular dose of interferon was 
administered, 7 x 10* units per kg per day for five days, 
beginning the evening before the operat ion. The mag-
nitude of virus shedding was greatly reduced post-
operatively in interferon vs placebo-receiving patients. 
One could also anticipate beneficial effects of inter-
feron in genital herpes, although effective therapy is 
already available in this instance wi th acyclovir (32). 
Interferon is also effective in decreasing the acute 
symptoms and possibly any recurrences of herpes 
simplex keratitis (41). In this disease, opt imal results 
were produced by combining t r i f luorothymidine wi th 
interferon (4). 
Interferon in Respiratory Diseases 
In experimentally-induced instances of the common 
cold in humans, intranasal application of leukocyte 
interferon resulted in the reduction of symptoms and 
virus shedding (42). Intranasal alpha interferon, pro-
duced by the recombinant DNA technique, also pre-
vented the experimental rhinovirus infection and illness 
in humans (43). However, intranasally administered 
interferon was not wi thout side effects. Some volun-
teers treated for five days or longer reported bleeding 
mixed wi th mucous nasal discharge and superficial er-
osions of the nasal mucosa (44). The most efficacious 
use of interferon against the common cold is likely to be 
by short, prophylactic administration. 
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Interferon has not been effective thus far in control l ing 
clinical influenza in humans. However, the virus is sen-
sitive to it. Wi th the increased availability of interferon 
and better ways of administration into the respiratory 
tree, clinical trials for the treatment of lower respiratory 
infections are urged (45). 
Antitumor Trials in Humans with Interferon 
This field was opened with the experimental work of 
Gresser (15). Strander, Cantell, and associates were 
successful in treating osteogenic sarcoma wi th pro-
longed intramuscular administration of leukocyte in-
terferon (46). A wel l -documented ant i tumor trial was 
conducted by Gutterman and coworkers, and partial 
remission was effected in 6 of 10 patients who had 
breast cancer and in 3 of the 6 mult iple myeloma cases. 
Four of the 11 patients wi th malignant lymphoma also 
showed some beneficial effect. The response to in-
terferon depended on the previous response to chemo-
t h e r a p y ; n o n e of t h e p a t i e n t s w h o had b e e n 
unresponsive to chemotherapy experienced a com-
plete remission when they were treated wi th interferon. 
Only 1 of 9 patients in this category had a partial remis-
sion (47). A tumor-reducing effect was noted when 
three patients who had nodular lymphoma were treated 
w i th human leukocyte in ter fe ron (48). Even more 
encouraging results were recently obtained when re-
combinant leukocyte interferon was administered to 
homosexual men who had Kaposi's sarcoma, producing 
a beneficial effect in 5 o f t he 13 (49). Similar results were 
reported f rom the National Institutes of Health (50). 
Alpha interferon induced in human leukocytes pro-
duced a remission in hairy-cell leukemia in all seven of 
the patients who were being treated by Quesada and 
associates (51). No other form of treatment has been 
found so consistently effective in this disease. Recom-
binant interferon showed some beneficial effect in 4 of 
the 8 patients who had advanced cancer (52). 
Interferon, applied intramuscularly and, particularly in-
tralesionally, was found to be effective in two patients 
with extensive tumor loads due to the human wart virus 
(53). 
Gamma interferon produced a greater ant i tumor effect 
in mice bearing sarcoma MC-36 than did a beta prep-
aration (54). Trials wi th this interferon for the treatment 
of cancer in men are not yet available for review. 
In summary, interferon may become an adjunct in anti-
tumor therapy. Whi le most of the effects observed in 
clinical trials were temporary and not eradicative, inter-
feron may yet become part of combination therapy for 
certain cancers. 
Undesired Side Effects of Interferon 
The clinical use of interferon is presently l imi ted, to a 
certain degree, by its many side effects (Table II). All 
appear to be reversible and most are dose dependent. 
The severity and frequency of side effects could have 
been affected by impurit ies in the earlier leukocyte 
preparations (55); however, pur i f ied, cloned interferon 
also produces undes i red effects wh ich are indis-
t inguishable f rom those seen wi th leukocytic inter-
feron. 
Virtually every patient receiving interferon experiences 
fever and chil ls, the severity of which is dependent on 
both dose and f requency of administrat ion (56-58). 
All three classes of interferon are pyrogenic. Both alpha 
and beta interferon were found to enhance the poten-
tial of human monocytes to produce the endogenous 
pyrogen, inter leukin-1 (59). However, exposure of 
interferon-pretreated monocytes to endotoxin was re-
quired for the actual secretion of inter leukin-1; inter-
feron alone was unable to induce its secretion. Whether 
the influenza-like, febri le illness caused by interferon is 
due to interleukin-1 is still undetermined. Some suggest 
that in ter feron is intr insical ly pyrogenic (a second 
endogenous pyrogen) (57,60). Interestingly, the pro-
duction of virus-induced interferon was enhanced by 
fever in rabbits (61). 
An even more l imit ing effect, also dose-dependent, is 
the excessive fatigue that many patients experience 
when treated with interferon. Unlike fever, this malaise 
tends to be cumulative and progressive (56). 
TABLE II 
Undesired Effects of Interferon 
Target Organ Dysfunction 
Systemic Fever, chills, anorexia, fatigue, myalgia 
Gastrointestinal Nausea, vomiting, diarrhea 
Hematologic Leukopenia, thrombocytopenia 
Renal Proteinuria 
Hepatic Increased transaminases and alkaline 
phosphatase, depression of cytochrome P-450 
Neurologic Headache, numbness, paresthesias, confusion, 
disorientation, seizures, abnormal EEG, 
drowsiness, irritability 
Endocrine Relative adrenal insufficiency 
Cardiac* Arrhythmias, myocardial infarction 
Immunologic Suppressed NK activity and antibody 
production 
•Likely secondary to systemic effects 
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Proteinuria has been occasionally described and can 
last up to two weeks after treatment is discontinued 
(56). In ter feron, injected alone or induced by lym-
phocytic choriomeningit is virus, was found to induce 
glomerular lesions in newborn mice (62,63). In a patient 
receiving recombinant interferon, interstitial nephritis 
presented as nephro t ic syndrome. The renal dys-
function was dose dependent and reversible (64). 
Hepatic structural damage was shown in interferon-
treated mice. In humans, transient elevations of trans-
aminases and alkaline phosphatase are frequent com-
plications of interferon administration (56). Neurologic 
dysfunct ion is not common ly detec ted, consist ing 
mainly of drowsiness, irritabil i ty, and confusion. How-
ever, all of the patients tested had abnormal electro-
encephalograms, even if they were otherwise normal 
neurologically (65). Even the heart appears to be affec-
ted by interferon, associated wi th arrhythmias and my-
ocardial infarction. However, most of the patients ob-
served were older and had evidence of preexisting 
heart disease. It is possible, therefore, that the systemic 
effects of interferon are a major cardiac stress (66). 
Relative adrenal insufficiency may also represent an 
undesired effect of interferon (67). 
The stimulatory and depressive effects of interferon on 
the immunologic system can be both beneficial and 
harmful to the host. In a trial w i th recombinant leu-
kocyte interferon, five cancer patients developed peri-
oral herpes simplex lesions after therapy was init iated. 
Although enhancement of natural killer cell activity by 
interferon has been frequently observed, interferon 
can also depress natural killer cytotoxicity in vivo (68). 
Lastly, interferon can affect the metabolism of other 
drugs through depression of the cytochrome P-450 sys-
tem, thus pro long ing the half-l i fe of drugs like di-
phenylhydantoin and possibly adenine arabinoside (69). 
Summary 
The role of interferon in the therapy of patients has not 
yet been defined and is a subject for cont inuing clinical 
studies. The availability of cloned interferon has prob-
ably shortened the interval required for investigational 
studies before therapeutic use. It is di f f icul t to project a 
date when inter feron wi l l be rout inely used in the 
Uni ted States. The demonst ra ted, albeit t ransient , 
effect of interferon in ant i tumor therapy may allow its 
introduct ion as an approved medicat ion. One could 
project a place for interferon in the treatment of chronic 
hepatitis B infect ion. Trials of interferon treatment of 
delta virus super-infections are also needed. Interferon 
is a broad spectrum antiviral agent inh ib i t ing most 
pathogenic viruses in experimental systems. Therefore, 
it may be useful in treating retrovirus-induced disease in 
humans. Catastrophic viral diseases, such as a viral 
encephalit is, may be considered for a trial of interferon. 
Respiratory virus disease is mostly self- l imit ing; since 
the side effects of interferon treatment seem to out-
weigh its therapeutic benefits, its use as a major ther-
apeutic aid seems unlikely. However, the local side 
effects may be avoided if short interferon courses are 
used prophylactically for the common co ld. Last, but 
not least, interferon treatment holds defini te promise in 
herpes virus infections characterized by latency and 
recrudescence. This may have part icular value for 
patients who are immunosuppressed. The t ime has 
arrived for the pract icing physician to become ac-
qua in ted w i th i n t e r f e ron , w i th its var ied b io log ic 
effects, and its potential in the therapy of viral and 
neoplastic diseases affecting humans. 
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